The firm plans to launch trials to study the agent in biomarker-defined cancer types, including breast and lung cancers.

Checkpoint Therapeutics Inc (CKPT) stock saw a decline, ending the day at $3.57 which represents a decrease of $-0.14 or -3.77% from the prior close of $3.71. The stock opened at $3.91 and touched a ...

Mersana Therapeutics is utilizing antibody-drug conjugates to target new immune checkpoints and revolutionize cancer ...

Plus: Next generation IVF, another successful pig-kidney transplant, worm secretions to treat inflammation, a new skin cancer ...

See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...

Through its collaboration with Nvidia, Genesis is working to accelerate development of its AI platform, Genesis Exploration ...

Checkpoint Therapeutics Inc (CKPT) stock saw a decline, ending the day at $3.39 which represents a decrease of $-0.28 or -7.63% from the prior close of $3.67. The stock opened at $4 and touched a low ...

Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) had its price objective hoisted by Lake Street Capital from $4.00 to $7.00 in a research note released on Monday morning,Benzinga reports. Lake ...

The Food and Drug Administration (FDA) has approved Unloxcyt™ (cosibelimab-ipdl) for the treatment of adults with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) ...

The FDA has approved cosibelimab (marketed under the brand name Unloxcyt), a new drug for adults with advanced cutaneous squamous cell carcinoma (CSCC), a type of skin cancer.

L1-blocking antibody is now approved for metastatic or locally advanced cutaneous SCC in adults who are not candidates for curative surgery or curative radiation.